An 82-year-old man with Worsening Gait
Neurol 89:e246-e252, Chew, S.,et al, 2017
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004